MBX Biosciences, Inc. Common Stock (MBX) vs NewAmsterdam Pharma Company N.V. (NAMS)
A side-by-side comparison of MBX Biosciences, Inc. Common Stock and NewAmsterdam Pharma Company N.V. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
MBX
MBX Biosciences, Inc. Common Stock
$57.29HealthcareDelayed quote: Oct 6, 2026, 11:24 AM EDT
NAMS
NewAmsterdam Pharma Company N.V.
$22.52HealthcareDelayed quote: Oct 6, 2026, 11:25 AM EDT
Total return — MBX vs NAMS
growth of $100 · dividends reinvested · last 2yMBX +147.5% (+57.3%/yr)NAMS +42.9% (+19.5%/yr)MBX compounded faster over this window
MBX NAMS
MBX vs NAMS: by the numbers
- •MBX is the larger company ($2.73B vs $2.63B market cap).
- •Both run net losses; MBX's is the smaller (0.00% vs -3644.21% net margin).
Metrics side by side
Valuation
| Metric | MBX | NAMS |
|---|---|---|
| P/S ratio | N/A | 369.62 |
| P/B ratio | 6.66 | 4.17 |
Profitability
| Metric | MBX | NAMS |
|---|---|---|
| Gross margin | 0.00% | 92.15% |
| Operating margin | 0.00% | -1002.90% |
| Net margin | 0.00% | -3644.21% |
| ROE | -25.47% | -41.10% |
| ROIC | -28.60% | -38.70% |
Growth (annualized)
| Metric | MBX | NAMS |
|---|---|---|
| Total return CAGR (5Y) | N/A | 18.30% |
Go deeper
Dig into the metrics
MBX Biosciences, Inc. Common Stock ROENewAmsterdam Pharma ROEMBX Biosciences, Inc. Common Stock operating marginNewAmsterdam Pharma operating marginMBX Biosciences, Inc. Common Stock revenue growthNewAmsterdam Pharma revenue growthMBX Biosciences, Inc. Common Stock free cash flowNewAmsterdam Pharma free cash flow
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.